Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Randall Schatzman

Murray Nguyen

Christine Gustin

Samara Violet

Jason Ptacek

Jenny Yuan

Seth M.

Lindsey Gourley

Anthony Wong

Kristi Balacy

Arthur Lee

Husein Hadeiba

Coya Tapia

Dawn Colburn

Willie Quinn

Lynn Ferguson Lewis

Pam Howland

Nathan Ihle

Grant Yonehiro

Michael N. Alonso

Wesley Burwell

Lu Xu

Sarah Nemec

The Laboratory Operations and Quality Control team at Bolt Biotherapeutics is responsible for ensuring the integrity and reliability of research and development processes. This team oversees laboratory practices, implements quality control measures, and manages biosample operations to maintain compliance with industry standards, ultimately supporting the advancement of innovative immune-stimulating antibody conjugates in the quest for effective immuno-oncology therapies.

Laboratory Operations and Quality Control

Leadership Team

Clinical Development and Research

Laboratory Operations and Quality Control

About

Team members

Other teams at Bolt Biotherapeutics

Leadership Team

Clinical Development and Research